Chronic Inflammatory Demyelinating Polyneuropathy CIDP
Conditions
Interventions
None listed
Sponsors
Amsterdam UMC, locatie AMC
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Possible, probable or definite clinical and electrophysiological EFNS/PNS criteria for CIDP (Group 1 and 2).5 In addition: A) Patients in Group 1 need to have active disease (history of progression justifying start or change of treatment as determined by treating physician). B) Patients in Group 2 with stable disease for three months on treatment with IVIg and/or corticosteroids. OR have a polyneuropathy associated with monoclonal IgM paraproteinemia (with or without anti-MAG antibodies) (Group 3, controls). - Adult males or females (18 year or more).
Exclusion criteria
Exclusion criteria: - Any concomitant disease (e.g. joint problems) or condition (e.g. misuse of alcohol) that might interfere with functionality of the patient, which could potentially interfere with capturing MCID changes related predominantly to CIDP. - Legally incompetent adults - No informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To define treatment response in CIDP using patient pMCID versus traditional MCID cut-offs on a linear disability scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) To determine whether pMCID during improvement is larger than the pMCID during deterioration. 2) To determine the margins of score fluctuation on the I-RODS during follow-up in patients with stable disease. | — |
Countries
Netherlands
Outcome results
None listed